Pioneering iPSC-Derived Cell Therapy & Regenerative Medicine
At Ricoh Biosciences, we leverage our proprietary iPSC differentiation technology to develop high-quality, functional cells for regenerative medicine and cell therapy applications. Our expertise in transcription factor-based differentiation allows us to rapidly generate clinically relevant cell types with high reproducibility, providing a scalable foundation for next-generation therapies.
Our Pipeline
| Indication | Cell Type | Discovery | Preclinical | IND | Phase 1 | Phase 2 | Phase 3 | Approval |
|---|---|---|---|---|---|---|---|---|
| Parkinson’s Disease (PD) | Dopaminergic Neurons |
|
||||||
| Alzheimer’s Disease (AD) | Excitatory Neurons |
|
||||||
| Alzheimer’s Disease (AD) | Microglia |
|
||||||
| Amyotrophic Lateral Sclerosis (ALS) | Motor Neurons |
|
||||||
| Multiple Sclerosis (MS) | Oligodendrocytes |
|
||||||
| Cancer | T-Cells |
|
||||||
Our Approach
We focus on advancing iPSC-derived cell therapies by:
- Developing high-quality, functional cell types for therapeutic use
- Optimizing differentiation protocols for clinical translation
- Establishing scalable manufacturing to meet regulatory and commercial requirements
Partnership Opportunities
We collaborate with partners to advance iPSC-derived therapies. Our flexible engagement model provides them with:
- Access too our proprietary iPSC differentiation technology
- Opportunities to co-develop cell therapies for clinical applications
- Scalable cell manufacturing capabilities to support clinical translation
How Can We Help?
"*" indicates required fields
Contact Us
Have a question about our products, services, or custom projects? Our team is here to help—reach out and we’ll get back to you as soon as possible.
Subscribe
By signing up you are agreeing to our Privacy Policy